Review
Version 1
Preserved in Portico This version is not peer-reviewed
Targeting Early Dementia: Using Lipid Cubic-Phase Nanocarriers to Cross the Blood-Brain Barrier
Version 1
: Received: 28 February 2018 / Approved: 28 February 2018 / Online: 28 February 2018 (07:49:13 CET)
A peer-reviewed article of this Preprint also exists.
D’Arrigo, J.S. Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood–Brain Barrier. Biomimetics 2018, 3, 4. D’Arrigo, J.S. Targeting Early Dementia: Using Lipid Cubic Phase Nanocarriers to Cross the Blood–Brain Barrier. Biomimetics 2018, 3, 4.
Abstract
Over past decades, a frequent co-morbidity of cerebrovascular pathology and Alzheimer's disease pathology has been observed. Numerous published studies indicate that preservation of healthy cerebrovascular endothelium can be an important therapeutic target. By incorporating appropriate drug(s) into biomimetic (lipid cubic-phase) nanocarriers, one obtains a multitasking combination therapeutic which targets certain cell-surface scavenger receptors, mainly class B type 1 (i.e., SR-BI), and crosses the blood-brain barrier. This targeting allows for various Alzheimer’s-related cell types to be simultaneously searched out for localized drug treatment in vivo.
Keywords
Alzheimer’s disease; biomimetic nanocarriers; blood-brain barrier; dementia; drug targeting; lipid cubic phases; nanoemulsion; SR-BI; scavenger receptors
Subject
Biology and Life Sciences, Biology and Biotechnology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
